Synthesis and pharmacological characterization of a novel nitric oxide-releasing diclofenac derivative containing a benzofuroxan moiety

Carvalho, Paulo Sergio de; Maróstica, Marta; Gambero, Alessandra; Pedrazzoli, José

doi:10.1016/j.ejmech.2010.02.034

Cited by 34 publications

(18 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NO‐NSAIDs consist in a parent NSAID covalently linked to a spacer that, in turn, is associated with a NO‐releasing moiety. In the last two decades, several NO‐NSAIDs have been synthesized using different spacers and NO‐donating moieties (Table ) . Most NO‐NSAIDs have an ester linkage but some were designed with a disulfide linker .…”

Section: Association Of Nsaids With Protective Mediatorsmentioning

confidence: 99%

Nonsteroidal Anti‐Inflammatory Therapy: A Journey Toward Safety

Pereira-Leite

Nunes

Jamal

et al. 2016

Medicinal Research Reviews

View full text Add to dashboard Cite

The efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) against inflammation, pain, and fever has been supporting their worldwide use in the treatment of painful conditions and chronic inflammatory diseases until today. However, the long-term therapy with NSAIDs was soon associated with high incidences of adverse events in the gastrointestinal tract. Therefore, the search for novel drugs with improved safety has begun with COX-2 selective inhibitors (coxibs) being straightaway developed and commercialized. Nevertheless, the excitement has fast turned to disappointment when diverse coxibs were withdrawn from the market due to cardiovascular toxicity. Such events have once again triggered the emergence of different strategies to overcome NSAIDs toxicity. Here, an integrative review is provided to address the breakthroughs of two main approaches: (i) the association of NSAIDs with protective mediators and (ii) the design of novel compounds to target downstream and/or multiple enzymes of the arachidonic acid cascade. To date, just one phosphatidylcholine-associated NSAID has already been approved for commercialization. Nevertheless, the preclinical and clinical data obtained so far indicate that both strategies may improve the safety of nonsteroidal anti-inflammatory therapy.

show abstract

Section: Association Of Nsaids With Protective Mediatorsmentioning

confidence: 99%

Nonsteroidal Anti‐Inflammatory Therapy: A Journey Toward Safety

Pereira-Leite

Nunes

Jamal

et al. 2016

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…Analogs that were able to release NO demonstrated antiaggregatory effects superior to the parent ibuprofen. In another NO‐donating NSAIDs‐based approach, Carvalho and fellow workers reported the synthesis of NO‐releasing diclofenac derivative bearing a benzofuroxan moiety . The compound, 1‐oxy‐benzo[1,2,5]oxadiazol‐5‐ylmethyl[2‐(2,6‐dichloro‐phenyl amino)‐phenyl] acetate ( 37 ) was synthesized by a reaction between diclofenac sodium and 5‐bromomethyl‐benzo[1,2,5] oxadiazole 1‐oxide.…”

Section: Development Of Various Nsaids and Their Derivativesmentioning

confidence: 99%

Recent Developments in Chimeric NSAIDs as Safer Anti‐Inflammatory Agents

Kumar

Sharma

2014

Medicinal Research Reviews

View full text Add to dashboard Cite

NSAIDs are among the most widely prescribed medications across the world, but the gastrointestinal (GI) toxicity still remains the biggest problem and the challenge for current NSAIDs-based therapeutics. The development of selective COX-2 inhibitors was driven by the assumption that selective inhibition of COX-2 would reduce the GI side effects. However, the initial enthusiasm for selective COX-2 inhibitors has faded away due to the emergence of serious side effects associated with the long-term use of these NSAIDs. In the recent years, a number of novel approaches to develop gastrosparing NSAIDs have been explored with the promising results. This review deals with such approaches and strategies that have been employed in the last two decades and are being used currently in the design and development of safer NSAIDs.

show abstract

“…This ester was found to be more effective in inhibiting PGE 2 synthesis than TXB 2 synthesis in vitro . This finding suggests that this NO-diclofenac ester is more selective for COX-2 [46]. …”

Section: No-nsaidsmentioning

confidence: 99%

Prodrugs of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), More Than Meets the Eye: A Critical Review

Qandil

2012

IJMS

112

View full text Add to dashboard Cite

The design and the synthesis of prodrugs for nonsteroidal anti-inflammatory drugs (NSAIDs) have been given much attention by medicinal chemists, especially in the last decade. As a therapeutic group, NSAIDs are among the most widely used prescribed and over the counter (OTC) medications. The rich literature about potential NSAID prodrugs clearly shows a shift from alkyl, aryalkyl or aryl esters with the sole role of masking the carboxylic acid group, to more elaborate conjugates that contain carefully chosen groups to serve specific purposes, such as enhancement of water solubility and dissolution, nitric oxide release, hydrogen sulfide release, antioxidant activity, anticholinergic and acetylcholinesterase inhibitory (AChEI) activity and site-specific targeting and delivery. This review will focus on NSAID prodrugs that have been designed or were, later, found to possess intrinsic pharmacological activity as an intact chemical entity. Such intrinsic activity might augment the anti-inflammatory activity of the NSAID, reduce its side effects or transform the potential therapeutic use from classical anti-inflammatory action to something else. Reports discussed in this review will be those of NO-NSAIDs, anticholinergic and AChEI-NSAIDs, Phospho-NSAIDs and some miscellaneous agents. In most cases, this review will cover literature dealing with these NSAID prodrugs from the year 2006 and later. Older literature will be used when necessary, e.g., to explain the chemical and biological mechanisms of action.

show abstract

Synthesis and pharmacological characterization of a novel nitric oxide-releasing diclofenac derivative containing a benzofuroxan moiety

Cited by 34 publications

References 20 publications

Nonsteroidal Anti‐Inflammatory Therapy: A Journey Toward Safety

Nonsteroidal Anti‐Inflammatory Therapy: A Journey Toward Safety

Recent Developments in Chimeric NSAIDs as Safer Anti‐Inflammatory Agents

Prodrugs of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), More Than Meets the Eye: A Critical Review

Contact Info

Product

Resources

About